Similarly, liposome-templated hydrogel nanoparticles (LHNPs) for CRISPR/Cas9 delivery were synthesized to knock out polo-like kinase1 (PLK1) gene in a mouse flank tumor model to inhibit tumor growth with higher efficiency than commercial agent Lipofectamine 2000 [105]. This evidence concerns the gene PLK1 and neoplasm.